Carter SK |
New drugs under clinical evaluation in the United States. |
1978 |
Cancer Chemother. Pharmacol. |
pmid:155503
|
Smith SV |
Technology evaluation: cantuzumab mertansine, ImmunoGen. |
2004 |
Curr. Opin. Mol. Ther. |
pmid:15663331
|
Liu Z et al. |
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. |
2005 |
J Mass Spectrom |
pmid:15674857
|
Lu SX et al. |
Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. |
2005 |
J Pharm Sci |
pmid:15729708
|
Hanka LJ and Barnett MS |
Microbiological assays and bioautography of maytansine and its homologues. |
1974 |
Antimicrob. Agents Chemother. |
pmid:15825322
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Lazar AC et al. |
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry. |
2005 |
Rapid Commun. Mass Spectrom. |
pmid:15945030
|
Wang L et al. |
Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. |
2005 |
Protein Sci. |
pmid:16081651
|
Smith SV |
Technology evaluation: huN901-DM1, ImmunoGen. |
2005 |
Curr. Opin. Mol. Ther. |
pmid:16121706
|
Frenzel T et al. |
Synthesis of the N-acetylcysteamine thioester of seco-proansamitocin. |
2006 |
Org. Lett. |
pmid:16381586
|